-transparent.png){kind=logo}
Intraperitoneal injection of ketamine (100 mg/kg body weight) significantly reduces the levels of cholecystokinin (CCK), somatostatin (SRIF), and substance P (SP)-like immunoreactivity in various regions of rat brain. No significant change in thyrotropin releasing hormone (TRH)-like immunoreactivity was observed. Neuropeptide systems may be involved in the neuropharmacologic effects of ketamine.
Related Publications
K Pongdhana, and
N Ogawa, and
Y Hirose, and
T Ono, and
F Kosaka, and
A Mori
August 1991,
Neuropeptides,
K Pongdhana, and
N Ogawa, and
Y Hirose, and
T Ono, and
F Kosaka, and
A Mori
May 1989,
Regulatory peptides,
K Pongdhana, and
N Ogawa, and
Y Hirose, and
T Ono, and
F Kosaka, and
A Mori
June 1981,
Endocrinology,
K Pongdhana, and
N Ogawa, and
Y Hirose, and
T Ono, and
F Kosaka, and
A Mori
August 1985,
Journal of neurochemistry,
K Pongdhana, and
N Ogawa, and
Y Hirose, and
T Ono, and
F Kosaka, and
A Mori
December 1986,
Digestive diseases and sciences,
K Pongdhana, and
N Ogawa, and
Y Hirose, and
T Ono, and
F Kosaka, and
A Mori
June 1988,
No to shinkei = Brain and nerve,
K Pongdhana, and
N Ogawa, and
Y Hirose, and
T Ono, and
F Kosaka, and
A Mori
January 1986,
Brain research,
K Pongdhana, and
N Ogawa, and
Y Hirose, and
T Ono, and
F Kosaka, and
A Mori
May 1988,
Experimental neurology,
K Pongdhana, and
N Ogawa, and
Y Hirose, and
T Ono, and
F Kosaka, and
A Mori
March 1999,
Japanese journal of pharmacology,
K Pongdhana, and
N Ogawa, and
Y Hirose, and
T Ono, and
F Kosaka, and
A Mori
November 1975,
Endocrinology,
